The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial
Open accessAbstract
Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 and P = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98; P = .03). Conclusions and Relevance: There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration: ClinicalTrials.gov identifier: NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Self-citationA Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Self-citationEMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Self-citationNeoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citation(2006) · Cancer · doi:10.1002/(issn)1097-0142 · Cited by 1,470
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Self-citationNeoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06651-x · Cited by 1,111
Self-citationHammel, P., Huguet, F., van Laethem, J.-L., Goldstein, D., Glimelius, B., Artru, P., Borbath, I., Bouché, O., Shannon, J., André, T., et al. (2016) · JAMA · doi:10.1001/jama.2016.4324 · Cited by 1,092
Self-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Self-citationGroot, V. P., Rezaee, N., Wu, W., Cameron, J. L., Fishman, E. K., Hruban, R. H., Weiss, M. J., Zheng, L., Wolfgang, C. L., & He, J. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002234 · Cited by 757
Murphy, J. E., Wo, J. Y., Ryan, D. P., Jiang, W., Yeap, B. Y., Drapek, L. C., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0329 · Cited by 531
Hackert, T., Sachsenmaier, M., Hinz, U., Schneider, L., Michalski, C. W., Springfeld, C., Strobel, O., Jäger, D., Ulrich, A., & Büchler, M. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001850 · Cited by 529
Self-citationLong-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Is Cure Possible?
Schnelldorfer, T., Ware, A. L., Sarr, M. G., Smyrk, T. C., Zhang, L., Qin, R., Gullerud, R. E., Donohue, J. H., Nagorney, D. M., & Farnell, M. B. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e3181613142 · Cited by 458
Katz, M. H. G., Shi, Q., Ahmad, S. A., Herman, J. M., Marsh, R. D. W., Collisson, E., Schwartz, L., Frankel, W., Martin, R., Conway, W., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.1137 · Cited by 448
Konstantinidis, I. T., Warshaw, A. L., Allen, J. N., Blaszkowsky, L. S., Castillo, C. F.-D., Deshpande, V., Hong, T. S., Kwak, E. L., Lauwers, G. Y., Ryan, D. P., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318263da2f · Cited by 424
Haeno, H., Gonen, M., Davis, M. B., Herman, J. M., Iacobuzio-Donahue, C. A., & Michor, F. (2012) · Cell · doi:10.1016/j.cell.2011.11.060 · Cited by 409
Patterns of Recurrence After Curative Resection of Pancreatic Cancer, Based on Autopsy Findings
Hishinuma, S., Ogata, Y., Tomikawa, M., Ozawa, I., Hirabayashi, K., & Igarashi, S. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2005.09.016 · Cited by 344
Winter, J. M., Brennan, M. F., Tang, L. H., D’Angelica, M. I., DeMatteo, R. P., Fong, Y., Klimstra, D. S., Jarnagin, W. R., & Allen, P. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1900-3 · Cited by 340
Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma
Van den broeck, A., Sergeant, G., Ectors, N., Van Steenbergen, W., Aerts, R., & Topal, B. (2009) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2008.12.006 · Cited by 307
Pancreatic Cancer Metastases Harbor Evidence of Polyclonality
Maddipati, R., & Stanger, B. Z. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0120 · Cited by 298
Campbell, F., Smith, R. A., Whelan, P., Sutton, R., Raraty, M., Neoptolemos, J. P., & Ghaneh, P. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03376.x · Cited by 258
Self-citationKayahara, M., Nagakawa, T., Ueno, K., Ohta, T., Takeda, T., & Miyazaki, I. (1993) · Cancer · doi:10.1002/1097-0142(19931001)72:7<2118::aid-cncr2820720710>3.0.co;2-4 · Cited by 248
Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., Mohile, S. G., Mumber, M., Schulick, R., Shapiro, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4948 · Cited by 224
Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches
Tuveson, D. A., & Neoptolemos, J. P. (2012) · Cell · doi:10.1016/j.cell.2011.12.021 · Cited by 188
Self-citationReconstructing metastatic seeding patterns of human cancers
Reiter, J. G., Makohon-Moore, A. P., Gerold, J. M., Bozic, I., Chatterjee, K., Iacobuzio-Donahue, C. A., Vogelstein, B., & Nowak, M. A. (2017) · Nature Communications · doi:10.1038/ncomms14114 · Cited by 170
Microscopic Margins and Patterns of Treatment Failure in Resected Pancreatic Adenocarcinoma
Gnerlich, J. L., Luka, S., Deshpande, A. D., DuBray, B. J., Weir, J. S., Carpenter, D. H., Brunt, E. M., Strasberg, S. M., Hawkins, W. G., & Linehan, D. C. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.1126 · Cited by 146
Wild, A. T., Hiniker, S. M., Chang, D. T., Tran, P. T., Khashab, M. A., Limaye, M. R., Laheru, D. A., Le, D. T., Kumar, R., Pai, J., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.044 · Cited by 77
Johnstone, P. A. S., & Sindelar, W. F. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90456-6 · Cited by 73
Suenaga, M., Fujii, T., Kanda, M., Takami, H., OKUMURA, N., Inokawa, Y., Kobayashi, D., Tanaka, C., Yamada, S., Sugimoto, H., et al. (2014) · PubMed · Cited by 59
Cited by
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Self-citationConroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3829 · Cited by 344
Self-citationPhillips, M. E., Robertson, M. D., Bennett-Eastley, K., Rowe, L., Frampton, A. E., & Hart, K. H. (2024) · Nutrients · doi:10.3390/nu16091269 · Cited by 11
Metadata
- Authors
- Jones, R. P., Psarelli, E.-E., Jackson, R., Ghaneh, P., Halloran, C. M., Palmer, D. H., Campbell, F., Valle, J. W., Faluyi, O., O’Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G. W., Cummins, S., Ross, P. J., Wasan, H., McDonald, A., Crosby, T., Ting, Y., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Lerch, M. M., Mayerle, J., Tjaden, C., Strobel, O., Hackert, T., Büchler, M. W., Neoptolemos, J. P., & for the European Study Group for Pancreatic Cancer
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2019-11-01
- Volume
- 154
- Issue
- 11
- Pages
- 1038
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W2972083722
- Cited by
- 274
- References
- 37
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.